Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Stock Information for Adagene Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adagene Inc.

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
Genenta Announces Euro20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.